7 recruiting, 6 completed, 3 active not recruiting, 3 terminated. 16 Phase 2, 9 Phase 1, 2 Phase 3.
Follow Nanoliposomal irinotecan: new trials by email Literature Review of Nanoliposomal irinotecan trials Research Report on Nanoliposomal irinotecan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations Biospecimen Collection, Computed Tomography, Fluorouracil - Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 94 | 2026-05-13 | 2026-05-22 |
| NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar Trial Biospecimen Collection, Computed Tomography, Fluorouracil - Borderline Resectable Pancreatic Ductal Adenocarcinoma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 20 | 2026-03-02 | 2026-09-21 |
| Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer Biopsy Procedure, Biospecimen Collection, Capecitabine - Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8 | Phase 3 | Recruiting | NRG Oncology | 356 | 2025-08-21 | 2026-08-25 |
| Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors Nanoliposomal irinotecan, Oxaliplatin, 5 fluorouracil - Small Bowel Adenocarcinoma | Phase 2 | Recruiting | Tiago Biachi de Castria | 36 | 2025-06-30 | 2026-07-28 |
| AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 AZD0901, 5-Fluorouracil, Leucovorin - Gastric Cancer, Gastroesophageal Junction Cancer | Phase 2 | Recruiting | AstraZeneca | 226 | 2023-12-13 | 2026-09-30 |
| A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC) Nanoliposomal irinotecan, 5 FU, Leucovorin - Metastatic Pancreatic Ductal Adenocarcinoma | Phase 2 | Recruiting | Belgian Group of Digestive Oncology | 134 | 2022-05-25 | 2025-02-06 |
| Spleen Irradiation With Nanoliposomal Irinotecan Plus 5-FU and Leucovorin in Metastatic Pancreatic Adenocarcinoma nanoliposomal irinotecan, spleen irradiation - Metastatic Pancreatic Cancer | Phase 2 | Unknown | National Taiwan University Hospital | 60 | 2022-05-01 | 2023-10-16 |
| Retrospective Study on the Efficacy and Tolerability of Liposomal Irinotecan Onivyde® + 5-FULV - Metastatic Pancreatic Ductal Adenocarcinoma | Unknown | University Hospital, Antwerp | 60 | 2021-09-27 | 2022-02-15 | |
| Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma Onivyde, Talazoparib, Temozolomide - Recurrent Solid Tumor, Recurrent Ewing Sarcoma | Phase 1 / Phase 2 | Recruiting | St. Jude Children's Research Hospital | 90 | 2021-06-09 | 2026-05-19 |
| Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma Onvansertib, Nanoliposomal irinotecan, Leucovorin - Pancreatic Ductal Adenocarcinoma | Phase 2 | Terminated | Cardiff Oncology | 41 | 2021-05-25 | 2026-11-04 |
| Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Bevacizumab, Irinotecan Sucrosofate - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 2 | Completed | Northwestern University | 3 | 2021-03-16 | 2023-01-19 |
| Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread Fluorouracil, Gemcitabine, Gemcitabine Hydrochloride - Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8 | Phase 2 | Active not recruiting | ECOG-ACRIN Cancer Research Group | 176 | 2020-08-26 | 2026-07-10 |
| MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Liposomal Irinotecan, Quality-of-Life Assessment, Questionnaire Administration - Locally Advanced Unresectable Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma | Phase 1 / Phase 2 | Withdrawn | University of Southern California | 2020-04-06 | 2020-03-27 | |
| Phase I Trial HIPEC With Nal-irinotecan nanoliposomal irinotecan - Peritoneal Cancer, Pseudomyxoma Peritonei | Phase 1 | Completed | Stony Brook University | 18 | 2019-10-22 | 2022-05-06 |
| NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer Nanoliposomal Irinotecan, Leucovorin, Fluorouracil - Advanced Biliary Tract Cancer | Phase 2 | Active not recruiting | Georgetown University | 48 | 2019-07-29 | 2026-10-27 |
| Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin Fluorouracil, Leucovorin, Liposomal Irinotecan - Locally Advanced Digestive System Neuroendocrine Carcinoma, Locally Advanced Pancreatic Neuroendocrine Carcinoma | Phase 2 | Terminated | Roswell Park Cancer Institute | 11 | 2019-06-17 | 2025-01-30 |
| Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors Nanoliposomal Irinotecan - Refractory Solid Tumors | Phase 1 | Completed | PharmaEngine | 44 | 2019-03-05 | 2023-11-18 |
| Nanoliposomal Irinotecan in Head & Neck and Esophagus After Prior Platinum-based Chemotherapy or Chemoradiotherapy nanoliposomal irinotecan - Head & Neck Cancer | Phase 2 | Completed | National Health Research Institutes, Taiwan | 59 | 2018-12-24 | 2023-04-11 |
| Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer Fluorouracil, Irinotecan Sucrosofate, Laboratory Biomarker Analysis - Metastatic Biliary Tract Carcinoma, Metastatic Colorectal Carcinoma | Phase 1 / Phase 2 | Unknown | Academic and Community Cancer Research United | 18 | 2018-11-02 | 2024-05-17 |
| TAS102 in Combination With NAL-IRI in Advanced GI Cancers Nanoliposomal Irinotecan, Trifluridine and Tipiracil Hydrochloride - Colorectal Adenocarcinoma, Gastric Adenocarcinoma | Phase 1 / Phase 2 | Active not recruiting | Emory University | 64 | 2018-01-30 | 2025-01-07 |
Showing 20 of 23. Sign in to see all of them.
Pancreatic Neoplasms (5) · Colorectal Neoplasms (3) · Stomach Neoplasms (3) · Biliary Tract Neoplasms (2) · Gastrointestinal Neoplasms (2) · Adenocarcinoma, Mucinous (1) · Fallopian Tube Neoplasms (1) · Glioblastoma (1) · Glioma (1) · Head and Neck Neoplasms (1) · Hepatoblastoma (1) · Mesothelioma (1) · Neoplasms (1) · Neoplasms, Cystic, Mucinous, and Serous (1) · Neuroblastoma (1)
Roswell Park Cancer Institute (2) · Academic and Community Cancer Research United (1) · AstraZeneca (1) · Belgian Group of Digestive Oncology (1) · Brown University (1) · Cardiff Oncology (1) · ECOG-ACRIN Cancer Research Group (1) · Emory University (1) · Georgetown University (1) · NRG Oncology (1) · National Cancer Institute (NCI) (1) · National Health Research Institutes, Taiwan (1) · National Taiwan University Hospital (1) · Northwestern University (1) · PharmaEngine (1)
United States (18) · Taiwan (4) · Canada (3) · Belgium (2) · Australia (1) · China (1) · Georgia (1) · Japan (1) · Malaysia (1) · Moldova (1) · Poland (1) · Singapore (1) · South Korea (1) · Spain (1) · United Kingdom (1)
Afsaneh Barzi, MD (1) · Benjamin Weinberg, MD (1) · Chia-Chi Lin, MD (1) · Christos Fountzilas (1) · Daniela E Matei, M.D. (1) · Efrat Dotan (1) · Georgios Georgakis, MD (1) · Howard Safran, MD (1) · Ivan Borbath (1) · Joseph Kim, MD (1) · Li-Yuan Bai, PhD (1) · Marc Peeters (1) · Minsig Choi, MD (1) · Nicholas Butowski, MD (1) · Nina N Sanford (1)
PMID 33284237, PMID 33835977, PMID 36410913, PMID 36963200, PMID 37010988, PMID 37600936, PMID 41117518
2019 (1), P30CA014089 (1), P30CA015083 (1), P30CA060553 (1), R21CA186140 (1), U10CA180820 (1), U10CA180868 (1), U10CA180888 (1), ZIABC011078 (1)